Valstar (Bladder Cancer) - Analysis and Forecasts to 2020


#28416

19pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, Valstar (Bladder Cancer) Analysis and Forecasts to 2020 provides Valstar global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information on Bladder Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Valstar including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Valstar including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Global sales forecast for 2009-2020 for Valstar

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of content

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 2

2 Introduction 4
2.1 Bladder Cancer Market 4
2.2 Bladder Cancer Disease 4
2.3 GlobalData Market Forecasts Report Guidance 7

3 Baldder Cancer Disease: Market Characterization 8
3.1 Bladder Cancer Disease Market 8
3.2 Bladder Cancer Disease Market Forecast and CAGR 8

4 TNM Classification of bladder cancer 9
4.1 American Urological Association 9

5 Valstar 12
5.1 Introduction 12
5.2 Mechanism of Action 12
5.3 Approval History of Valstar 12
5.4 Sales Drivers 13
5.4.1 Bladder Cancer Market 13
5.4.2 Large Unmet Need 13
5.4.3 BCG has limited use in second line therapy 13
5.5 Drug Benefit Risk Score 13
5.5.1 Efficacy 14
5.5.2 Safety 14
5.5.3 Compliance 14
5.5.4 Dosing Convenience 14
5.6 Sales forecast 15
5.6.1 Target patient Pool of Valstar 15
5.6.2 Market Penetration 15
5.6.3 Annual Cost of Therapy 16
5.6.4 Market Potential of Drug Valstar 16
5.6.5 Sales Projections of Valstar 16

6 Bladder Cancer Market: Appendix 17
6.1 Market Definitions 17
6.2 List of Abberiviations 17
6.3 Research Methodology 17
6.3.1 Coverage 17
6.3.2 Secondary Research 17
6.3.3 Forecasting 18
6.3.4 Number of Patients Approved to take the Drug 18
6.3.5 Net Penetration of Drug 18
6.3.6 Net Annual Dosing 18
6.3.7 Annual Cost of Therapy 19
6.3.8 Primary Research 19
6.3.9 Expert Panels 19
6.4 Contact Us 19
6.5 Disclaimer 19
6.6 Sources 19


Table 1: Bladder Cancer Global Market Forecast ($bn) 2002-2020 8
Table 2: Drug Risk Benefit Score 14


Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 4
Figure 2: Bladder Cancer Incidences & Mortality 5
Figure 3: Difference Of Percent Distribution of Incidence & Percent Distribution of Mortality of Top 20 Cancers 5
Figure 4: Percent Share of Risk Factors & Declining Smoking Curves 6
Figure 5: Percent Share of Risk Factors & Declining Smoking Curves 6
Figure 6: Percent Share of Risk Factors & Declining Smoking Curves 7
Figure 7: Percent Share of Risk Factors & Declining Smoking Curves 7
Figure 8: Forecasted Global Bladder Cancer Market 8
Figure 9: Broad Classification of Bladder Cancer 9
Figure 10: Classification of NMI Bladder Cancer 9
Figure 11: Detailed TNM Classifications 10
Figure 12: Classification of NMI Bladder Cancer 10
Figure 13: Valstar Approval History 12
Figure 14: Comparison of Drug benefit Score of Valstar with its Competing Drugs 13
Figure 15: Drug Model Diagram of Valstar 15
Figure 16: Competitors of Valstar Drug 16
Figure 17: Global Forecasted Sales of Valstar 17